ArticleInfection and drug resistance2018
Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant.
Article in Infection and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Understanding Basic Concepts of Viral Quasispecies: From Evolutionary Dynamics to Clinical Relevance.Pathogens (Basel, Switzerland) · 2026Review
- Deep Sequencing Analysis of Hepatitis C Virus Subtypes and Resistance-Associated Substitutions in Genotype 4 Patients Resistant to Direct-Acting Antiviral (DAA) Treatment in Egypt.International journal of molecular sciences · 2025Article
- Identification of Various Recombinants in a Patient Coinfected With the Different SARS-CoV-2 Variants.Influenza and other respiratory viruses · 2024Article
- In-Host Flat-like Quasispecies: Characterization Methods and Clinical Implications.Microorganisms · 2024Article
- Looking at the Molecular Target of NS5A Inhibitors throughout a Population Highly Affected with Hepatitis C Virus.Pathogens (Basel, Switzerland) · 2023Article
- Atypical Mutational Spectrum of SARS-CoV-2 Replicating in the Presence of Ribavirin.Antimicrobial agents and chemotherapy · 2023Article
- SARS-CoV-2 Mutant Spectra at Different Depth Levels Reveal an Overwhelming Abundance of Low Frequency Mutations.Pathogens (Basel, Switzerland) · 2022Article
- SARS-CoV-2 Point Mutation and Deletion Spectra and Their Association with Different Disease Outcomes.Microbiology spectrum · 2022Article
- Review
- Efficacy decrease of antiviral agents when administered to ongoing hepatitis C virus infections in cell culture.Frontiers in microbiology · 2022Article
- Host-dependent editing of SARS-CoV-2 in COVID-19 patients.Emerging microbes & infections · 2021Article
- The Role of RASs /RVs in the Current Management of HCV.Viruses · 2021Review
- Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.BMC infectious diseases · 2021Article
- Article
- Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols.Virology journal · 2020Article
- Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection.Frontiers in microbiology · 2020Article
- Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges.International journal of medical sciences · 2020Review
- Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype.Infection and drug resistance · 2019Article
- Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment.Infection and drug resistance · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundControversy is ongoing about whether a minority mutant present at frequencies below 15% may be clinically relevant and should be considered to guide treatment.
methodsResistance-associated substitution (RAS) studies were performed in patients before and at failure of antiviral treatments using Next-generation hepatitis C virus (HCV) sequencing (NGS).
resultsWe have found two patients with genotype 1a infection having RAS in 3.5%-7.1% of the viral population at baseline that were selected during ledipasvir + sofosbuvir treatment. Co-selection of RAS located in a region not directly affected by the antiviral treatment also occurred. This observation calls into question, the recommendations to guide RAS-based direct-acting antiviral (DAA) treatment only when RAS are present in >15% of the sequences generated.
conclusionOur results suggests that RAS study should include all three HCV DAA target proteins and minority mutants should be considered as clinically relevant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.